ClinicalTrials.gg
CompletedNCT04506944Updated Oct 5, 2023

The Epidemiology of Rickettsial Infections in South India: Cohort Study

An observational study in Scrub Typhus, Spotted Fever; India and Murine Typhus, sponsored by London School of Hygiene and Tropical Medicine. Completed at 1 site in India. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by London School of Hygiene and Tropical Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32,566
Sex
All
01

Study summary

There is enough evidence to suggest that scrub typhus and spotted fever group rickettsioses are common causes of febrile illness in India. Serological evidence also exists for murine typhus, but is rarely tested for. Incidence, risk factors, clinical features and molecular epidemiology of these three infections are poorly understood. Delays in disease recognition and treatment may cause thousands of preventable deaths across India.

The objectives of the research are to determine the incidence and risk factors of scrub typhus, spotted fever and murine typhus by severity, to determine clinical features of these neglected and often unrecognized infections. Further to study the effect of previous infection on incidence and severity of subsequent infections. Finally to study the association between vector parameters and scrub typhus risk.

Enrolled will be 30,000 individuals who will be followed up for the development of fever using active and passive surveillance. Active surveillance will include household screening every 3-6 weeks. Fever cases occuring in the past two months will be tested for Scrub typhus, murine typhus and spotted fever IgG/IgM. 4000 individuals will be followed up by annual serological testing to identify asymptomatic infections. Participants notifying the study team with ongoing fever will undergo blood testing for acute diagnosis of rickettsial infection (IgM, PCR). In addition, we will enroll fever cases at study clinics who are not part of the main cohort. The research includes spatial and socio-economic risk factor analysis. Rodents carrying mite larvae will be trapped to compare the intensity of mite infestation between areas of high and low risk for human scrub typhus.

The data on incidence, burden of disease and environmental determinants of scrub typhus, spotted fever and murine typhus will be used for health care planning and information campaigns for the public and medical professionals.

Read the detailed description

The aim of the cohort study is to better understand the epidemiology, sero-epidemiology and transmission of scrub typhus, murine typhus and tick-borne spotted fever. The overall focus of the work will be on scrub typhus, being the most important of the three from the public health perspective. We aim to determine the "severity pyramid" of serological, symptomatic and severe infection. The results from this study will help clinicians to understand the natural course of scrub typhus infection, health policy makers to estimate the global burden and the scope for community-based interventions, and immunologists to better understand the immunogenicity of single and repeat infections.

The specific objectives are to:

  1. Estimate the incidence of symptomatic and severe scrub typhus infection in the community.
  2. Estimate the incidence of serological (asymptomatic) scrub typhus infection.
  3. Estimate the effect of previous scrub typhus infection (sero-positive at baseline) on the risk of subsequent infection and disease severity (subclinical vs clinically apparent). This includes the effect of antibodies in mothers on the risk of severe infection in young children via residual maternal antibodies.
  4. Estimate the effect of potential risk factors such as age, gender, occupation, water/sanitation access and comorbidity on the risk of scrub typhus infection.
  5. Estimate the effect of spatial-temporal risk factors for scrub typhus by identifying high risk areas, accounting for human population density and land use.
  6. Compare the rate of rodent trappings and vector parameters of chiggers between high risk and low risk areas identified under 5).
  7. Estimate the disease burden associated with scrub typhus and the economic impact of scrub typhus in terms of loss of earnings and health expenditure.
  8. Estimate the incidence of asymptomatic and symptomatic murine typhus and spotted fever infection and explore associated socio-demographic, spatial and vector-related risk factors.

STUDY OVERVIEW

The study will be a population-based cohort study over two years (i.e. two scrub typhus seasons) in about 30,000 people living in approximately 40 villages with a sero-prevalence of at least 15% (see flow diagram above). These individuals will be followed-up through active surveillance for recent febrile illnesses (clinical cohort). For passive surveillance, participants will be encouraged to notify the study team in case of fever or come to one of 4 local study clinics. At study clinics we will also enrol fever cases who are not part of the clinical cohort, i.e. have not been enrolled prior to their fever. The study will include a smaller cohort (sero-cohort) for serological surveillance of 4000 people drawn from the 30,000 people of the clinical cohort. Longitudinal serological surveys linked to active surveillance are essential to estimate true attack rates unbiased by disease severity. The sero-cohort will consist of three annual blood testing in the same group of participants over two scrub typhus seasons (baseline, inter-season, endline).

Target population- A pilot study showed that scrub typhus infection is highly focal This makes it difficult to define a target population for the purpose of making inferences. We will define the target population in terms of the village level sero-prevalence. The aim is to correlate the incidence of scrub typhus with the sero-prevalence at village level. This will allow using the results of the study to predict the expected incidence and burden of scrub typhus in other settings with a known sero-prevalence, and eventually estimate the global burden of scrub typhus (not part of the study but a potential extension of the work). The target population for the study is therefore "villages in which the IgG sero-prevalence is at least 15%".

02

Conditions studied

  • Scrub Typhus
  • Spotted Fever; India
  • Murine Typhus
03

In context

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

General population cohort: all residents in scrub typhus endemic villages Serological cohort: random sample of 4000 individuals older than 10 years present at the time of the initial baseline survey visit

hospital case cohort: cases of all ages attending study clinics for undifferentiated fever of at least 5 days duration

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General population cohort: residing in study villages
  • serological cohort: aged 10 years or older
  • Hospital cohort: all ages

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32,566 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • General population

    Whole population of scrub typhus endemic villages

    Other: No intervention

  • hospital case population

    cases recruited at study clinics who are not enrolled in general population cohort

    Other: No intervention

  • Serological cohort

    random subset of 4000 participants above the age of 10 drawn from general population cohort

    Other: No intervention

Interventions

  • OtherNo intervention

    No specific exposure is explored.

06

What researchers measure

Primary outcomes

  1. Incidence of scrub typhus

    clinically apparent infection

    Time frame: 2 years

  2. Incidence of spotted fever

    clinically apparent infection

    Time frame: 2 years

  3. Incidence of murine typhus

    clinically apparent infection

    Time frame: 2 years

Secondary outcomes

  1. Incidence of serological infection (scrub typhus)

    measured using paired samples from sero-cohort

    Time frame: 2 years

  2. Incidence of serological infection (spotted fever)

    measured using paired samples from sero-cohort

    Time frame: 2 years

  3. Incidence of serological infection (murine typhus)

    measured using paired samples from sero-cohort

    Time frame: 2 years

  4. Incidence of complicated infection (scrub typhus)

    based on pre-defined complications: ARDS, shock, CNS, renal failure, myocarditis

    Time frame: 2 years

  5. Incidence of complicated infection (spotted fever)

    based on pre-defined complications: ARDS, shock, CNS, renal failure, myocarditis

    Time frame: 2 years

  6. Incidence of complicated infection (murine typhus)

    based on pre-defined complications: ARDS, shock, CNS, renal failure, myocarditis

    Time frame: 2 years

07

Study locations

1 site
  • Christian Medical College
    Vellore, Tamil Nadu 632004, India
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — de-identified case data will be made available at LSHTMs data repository

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: from 12/2022 indefinitely

Access criteria: on request

Data sharing details ↗ · datacompass.lshtm.ac.uk

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Aug 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 10, 2020
StartActual
Aug 1, 2020
Primary completionActual
Aug 5, 2022
CompletionActual
Jul 31, 2023
Last update
Oct 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04506944
Collaborators
Medical Research Council, Christian Medical College, Vellore, India, Mahidol Oxford Tropical Medicine Research Unit, Australian Rickettsial Reference Laboratory
Responsible party
Sponsor
First posted
Aug 10, 2020
Start date
Aug 1, 2020
Primary completion
Aug 5, 2022
Completion
Jul 31, 2023
Last update
Oct 5, 2023

Study contacts

Wolf-Peter Schmidt, PhD
principal investigator · London School of Hygiene and Tropical Medicine
Daniel Chandramohan, PhD
study chair · London School of Hygiene and Tropical Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion